These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 17495881

  • 1. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Séronie-Vivien S, LeCesne A, Vassal G, Innovative Therapies with Children with Cancer European consortium.
    Clin Cancer Res; 2008 Nov 01; 14(21):7102-9. PubMed ID: 18981009
    [Abstract] [Full Text] [Related]

  • 3. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.
    Ther Drug Monit; 2011 Apr 01; 33(2):244-50. PubMed ID: 21311410
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
    Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H.
    Clin Pharmacol Ther; 2011 Jul 01; 90(1):157-63. PubMed ID: 21633340
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [Abstract] [Full Text] [Related]

  • 7. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
    Vivona D, Bueno CT, Lima LT, Hirata RD, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM.
    Blood Cells Mol Dis; 2012 Feb 15; 48(2):132-6. PubMed ID: 22134106
    [Abstract] [Full Text] [Related]

  • 8. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G.
    Haematologica; 2008 Aug 15; 93(8):1252-5. PubMed ID: 18519520
    [Abstract] [Full Text] [Related]

  • 9. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY, Kan E, Lim WY, Chay G, Law JH, Soo GW, Bukhari NI, Segarra I.
    J Pharm Pharmacol; 2011 Jul 15; 63(7):918-25. PubMed ID: 21635257
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T.
    Br J Clin Pharmacol; 2006 Jul 15; 62(1):97-112. PubMed ID: 16842382
    [Abstract] [Full Text] [Related]

  • 11. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y, Sheng Y.
    Liver Transpl; 2006 May 15; 12(5):775-80. PubMed ID: 16628701
    [Abstract] [Full Text] [Related]

  • 12. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
    Di Paolo A, Polillo M, Capecchi M, Cervetti G, Baratè C, Angelini S, Guerrini F, Fontanelli G, Arici R, Ciabatti E, Grassi S, Bocci G, Hrelia P, Danesi R, Petrini M, Galimberti S.
    Pharmacogenomics J; 2014 Aug 15; 14(4):328-35. PubMed ID: 24589908
    [Abstract] [Full Text] [Related]

  • 13. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR.
    Bone Marrow Transplant; 2009 Aug 15; 44(3):169-74. PubMed ID: 19204709
    [Abstract] [Full Text] [Related]

  • 14. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D.
    J Clin Oncol; 2007 Mar 20; 25(9):1107-13. PubMed ID: 17369574
    [Abstract] [Full Text] [Related]

  • 15. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ.
    Pharmacopsychiatry; 2007 May 20; 40(3):93-102. PubMed ID: 17541883
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M.
    Cancer Chemother Pharmacol; 2004 Oct 20; 54(4):290-4. PubMed ID: 15138710
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini MR.
    Cancer Chemother Pharmacol; 2014 Jul 20; 74(1):85-93. PubMed ID: 24817601
    [Abstract] [Full Text] [Related]

  • 18. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX, Molimard M.
    Leuk Res; 2009 Aug 20; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract] [Full Text] [Related]

  • 19. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H.
    J Clin Oncol; 2006 Jun 01; 24(16):2448-55. PubMed ID: 16651648
    [Abstract] [Full Text] [Related]

  • 20. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O, Chan JY, Lin K, Heng CC, Chowbay B.
    PLoS One; 2012 Jun 01; 7(12):e51771. PubMed ID: 23272163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.